List of Excipients in Branded Drug IYUZEH

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Thea Pharma Inc	IYUZEH	latanoprost ophthalmic solution 0.005%	82584-003	CARBOMER HOMOPOLYMER TYPE B
Thea Pharma Inc	IYUZEH	latanoprost ophthalmic solution 0.005%	82584-003	EDETATE DISODIUM
Thea Pharma Inc	IYUZEH	latanoprost ophthalmic solution 0.005%	82584-003	POLYETHYLENE GLYCOL 4000
Thea Pharma Inc	IYUZEH	latanoprost ophthalmic solution 0.005%	82584-003	POLYOXYL 40 HYDROGENATED CASTOR OIL

IYUZEH Excipient Strategy and Commercial Opportunities for Preservative-Free Latanoprost

Last updated: August 1, 2026

IYUZEH is a preservative-free ophthalmic solution containing latanoprost 0.005% for reducing elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. Its commercial differentiation depends on formulation design, container compatibility, sterility assurance, dosing convenience, and preservative-free positioning rather than on a new active ingredient.[1]

The principal excipient opportunity is to develop alternative preservative-free latanoprost systems that maintain chemical stability, minimize ocular irritation, support multidose delivery, and comply with FDA ophthalmic quality requirements. Potential commercial products include authorized generics, private-label products, alternative bottle systems, single-dose presentations, and follow-on formulations that improve usability or reduce manufacturing cost.

What is IYUZEH and how does its formulation differ from conventional latanoprost?

IYUZEH is a preservative-free formulation of latanoprost ophthalmic solution 0.005%. The product is administered as one drop in the affected eye once daily, generally in the evening. It is indicated for open-angle glaucoma and ocular hypertension.[1]

Conventional latanoprost products commonly contain benzalkonium chloride, or BAK, as a preservative. IYUZEH eliminates BAK and uses a sterile, single-dose or preservative-free multidose delivery strategy. The absence of BAK addresses concerns associated with chronic exposure to preservatives, including ocular surface irritation and tear-film effects.

IYUZEH formulation profile

Attribute	IYUZEH profile
Active ingredient	Latanoprost
Strength	0.005%
Dosage form	Ophthalmic solution
Route	Topical ocular
Preservative	Preservative-free
Indications	Open-angle glaucoma; ocular hypertension
Dosing	One drop once daily
Storage	Refrigerated before opening; product-specific storage after opening
FDA application	NDA 217951
FDA approval	December 2023
Commercial sponsor	Thea Pharma

The formulation uses a buffered aqueous vehicle. The FDA prescribing information identifies glycerin, sodium citrate dihydrate, citric acid monohydrate, sodium hydroxide, and water for injection among the inactive ingredients.[1]

What excipients are used in IYUZEH?

IYUZEH uses a relatively simple excipient system centered on pH control, tonicity, and aqueous stability.

Glycerin

Glycerin functions primarily as a tonicity-adjusting agent. In an ophthalmic product, osmolality affects comfort, tolerability, and ocular surface response. The excipient also contributes to the physical properties of the solution and can influence drop formation during administration.

Sodium citrate dihydrate and citric acid monohydrate

The citrate system provides buffering capacity. Buffer selection is important because latanoprost is susceptible to degradation under unsuitable pH, light, temperature, and aqueous conditions. The buffer must provide adequate pH control without creating excessive ocular irritation or destabilizing the active ingredient.

Sodium hydroxide

Sodium hydroxide is used for pH adjustment. Its commercial importance is small in volume terms but significant in formulation control. Small pH changes can affect latanoprost stability, comfort, preservative-free sterility strategy, and compatibility with the container closure system.

Water for injection

Water for injection is the aqueous vehicle. The manufacturing process must control bioburden, endotoxin, particulate matter, and microbial contamination. A preservative-free ophthalmic formulation requires process controls that compensate for the absence of antimicrobial protection in the finished product.

How does IYUZEH’s preservative-free excipient strategy create commercial value?

The commercial value comes from removing BAK while retaining a familiar active ingredient, dose, and indication. The product can target patients who experience ocular-surface intolerance, clinicians who prefer preservative-free therapy, and treatment settings in which chronic exposure to BAK is a concern.

The formulation strategy creates four commercial advantages:

1. It differentiates latanoprost from established BAK-containing products.
2. It supports premium pricing relative to commodity generic latanoprost.
3. It creates a platform for preservative-free glaucoma products using other prostaglandin analogues.
4. It shifts competitive emphasis toward delivery systems, packaging, adherence, and tolerability.

The opportunity is strongest where the product can demonstrate practical advantages without requiring a new active ingredient. Those advantages may include reduced burning, lower ocular-surface burden, improved usability for chronic therapy, and fewer concerns about preservative exposure.

What formulation patents protect IYUZEH?

IYUZEH’s intellectual-property position is likely to rely primarily on formulation, stability, manufacturing, and container-closure claims rather than composition-of-matter protection for latanoprost. Latanoprost itself is an established active ingredient with generic competition.

Potential claim categories include:

• Preservative-free latanoprost solutions.
• Specific citrate-buffered formulations.
• Defined pH and osmolality ranges.
• Stability profiles under refrigerated and in-use conditions.
• Multidose containers that prevent microbial contamination without conventional preservatives.
• Manufacturing methods for sterile filling.
• Packaging configurations that limit oxygen, light, or microbial ingress.
• Methods of treating glaucoma or ocular hypertension with the preservative-free formulation.

The relevant FDA application is NDA 217951. FDA approval records identify IYUZEH as a prescription ophthalmic product approved in December 2023.[1] Patent scope and Orange Book listing status should be evaluated against the current FDA Orange Book and the applicable United States Patent and Trademark Office records because listed patents and expiration data can change through corrections, disclaimers, pediatric extensions, litigation, or regulatory updates.[2]

What is the Orange Book status of IYUZEH?

IYUZEH is listed as an FDA-approved prescription drug under NDA 217951. The commercial significance of any Orange Book patent listing is that an abbreviated new drug application applicant may need to submit a Paragraph IV certification against listed patents or wait for patent expiry before commercial launch.

For IYUZEH, the principal regulatory question is not whether latanoprost is generic. It is whether a proposed generic can avoid, invalidate, or successfully challenge patents covering the preservative-free formulation, delivery system, or method of use.

When does IYUZEH lose exclusivity?

IYUZEH’s commercial exclusivity has several layers:

Exclusivity layer	Commercial relevance
New drug approval	Establishes NDA-based FDA approval for the product
Formulation patents	May delay or complicate preservative-free generic entry
Container and delivery patents	May require a competing device or alternative presentation
Method-of-use patents	May affect labeling strategy and certification risk
Regulatory exclusivity	Depends on the FDA exclusivity designation and application history
Trade secrets	May protect manufacturing parameters not disclosed in the label

Latanoprost’s active-ingredient exclusivity does not protect the product in the same way as a new chemical entity. The central barrier is therefore the enforceability and breadth of formulation and delivery patents, coupled with the technical difficulty of reproducing a stable, sterile, preservative-free ophthalmic product.

A generic applicant could pursue several launch paths:

• Submit an ANDA with a formulation that falls outside asserted patent claims.
• Submit a Paragraph IV certification challenging listed patents.
• Use a different buffer or tonicity system.
• Use a different preservative-free multidose container.
• Use unit-dose packaging rather than a multidose bottle.
• Accept a commercial launch date under a settlement agreement.
• Launch after patent expiry without challenging the listed patents.

What Paragraph IV challenges could affect IYUZEH?

A Paragraph IV challenge would most likely focus on the formulation or delivery claims rather than the latanoprost molecule. Typical arguments could include:

• The claimed buffer system is obvious in view of prior ophthalmic formulations.
• The claimed pH or osmolality range lacks adequate written description.
• The formulation does not produce an unexpected stability or tolerability benefit.
• The delivery container does not provide a technically distinctive sterile barrier.
• The patent claims are anticipated by earlier preservative-free latanoprost products.
• The method-of-use claims are obvious based on known concerns about BAK exposure.

A first-filer opportunity could create 180-day generic exclusivity if statutory requirements are satisfied. The value of that opportunity depends on whether the patent estate blocks only one formulation pathway or the broader preservative-free latanoprost category.

What formulation alternatives could compete with IYUZEH?

Alternative buffer systems

Competitors could evaluate phosphate, borate, acetate, or alternative citrate systems. Each option creates tradeoffs involving pH control, ocular tolerability, active-ingredient stability, precipitation risk, and compatibility with the container.

Alternative tonicity agents

Sodium chloride, mannitol, sorbitol, and other polyols may substitute for or supplement glycerin. The selected agent must preserve drop comfort and avoid unwanted effects on solution viscosity, osmolality, or container performance.

Antioxidant and chelator systems

Latanoprost stability may be affected by oxidation and trace-metal catalysis. Formulators could investigate chelating agents or antioxidant strategies, subject to ophthalmic safety, regulatory acceptability, and patent clearance. Such changes could create new intellectual property if they produce a measurable stability advantage.

Unit-dose packaging

Single-use ampoules eliminate the need for in-use antimicrobial protection. They can reduce contamination risk but raise packaging, shipping, waste, and patient-convenience costs.

Preservative-free multidose bottles

Multidose preservative-free systems offer better convenience and lower packaging waste. The technical barrier is greater because the bottle, valve, nozzle, cap, and filling process must limit microbial ingress throughout the labeled in-use period.

How strong is the IYUZEH patent estate?

The strength of the estate depends on claim breadth and the availability of non-infringing formulation routes.

Patent strategy	Relative blocking potential
Broad preservative-free latanoprost composition claims	High if valid and difficult to design around
Narrow citrate-buffer claims	Moderate; alternative buffers may be available
Defined pH and osmolality claims	Moderate; design-around may be possible
Multidose delivery-system claims	Moderate to high for products using the same device architecture
Sterile manufacturing claims	Variable; process claims can be difficult to detect and enforce
Method-of-use claims	Variable; labeling and induced-infringement issues affect value
Stability claims	Moderate if supported by strong comparative data

The estate is commercially stronger when formulation claims cover the active ingredient, excipient ratios, pH, stability profile, and delivery container in combination. It is weaker if each claim is narrow and competitors can use a different buffer, tonicity agent, or package while achieving equivalent product performance.

What manufacturing and intellectual-property barriers exist?

Preservative-free ophthalmic manufacturing creates barriers that are separate from patent protection.

Key technical requirements include:

• Sterile compounding and filling.
• Validated aseptic processing.
• Low particulate levels.
• Control of endotoxins and bioburden.
• Container-closure integrity.
• Stability through refrigerated storage and in-use handling.
• Reliable drop size and dose delivery.
• Compatibility between formulation and bottle materials.
• Protection from light and oxidation.
• Consistent performance after repeated opening.

A technically acceptable generic must show pharmaceutical equivalence and demonstrate that the container system does not introduce a meaningful microbial or dosing risk. The development cost and regulatory burden may reduce the number of credible competitors even when patent barriers are manageable.

Which companies are challenging or competing with IYUZEH?

The competitive field includes:

• Generic manufacturers selling conventional BAK-containing latanoprost.
• Developers of preservative-free latanoprost.
• Manufacturers of tafluprost, bimatoprost, and travoprost.
• Ophthalmic device companies supplying preservative-free multidose systems.
• Contract development and manufacturing organizations with sterile ophthalmic capabilities.

The closest product-level competitors are not limited to latanoprost. Clinicians may switch among prostaglandin analogues based on efficacy, tolerability, price, formulary access, and dosing convenience. A preservative-free product must therefore compete against both low-cost generic latanoprost and branded alternatives with established physician familiarity.

How does IYUZEH compare with conventional generic latanoprost?

Factor	IYUZEH	Conventional generic latanoprost
Active ingredient	Latanoprost	Latanoprost
Strength	0.005%	Usually 0.005%
Preservative	Preservative-free	Commonly BAK-containing
Differentiation	Ocular-surface and delivery profile	Price and availability
Manufacturing complexity	Higher	Lower relative complexity
Packaging cost	Higher	Generally lower
Patent risk	Formulation and delivery focused	Primarily residual product and regulatory issues
Pricing potential	Premium or protected niche	Commodity-oriented
Substitution risk	High from generic latanoprost	High from competing generics

IYUZEH’s commercial position depends on maintaining a meaningful clinical or practical distinction. If payers treat preservative-free latanoprost as therapeutically interchangeable with low-cost generic products, price pressure will increase.

What licensing deals and partnership opportunities exist?

The most attractive licensing opportunities are likely to involve technology rather than the latanoprost active ingredient itself.

Potential deal structures include:

• Regional rights for IYUZEH or a comparable preservative-free product.
• Licensing of preservative-free multidose bottle technology.
• Co-development of preservative-free glaucoma products.
• Contract manufacturing agreements for sterile ophthalmic filling.
• Authorized generic commercialization.
• Private-label supply for pharmacy or payer channels.
• Platform licenses covering prostaglandin analogues beyond latanoprost.

A device owner could license a validated multidose container to multiple ophthalmic products. A formulation company could license a stability-enhancing excipient system to manufacturers seeking a differentiated latanoprost product. The highest value generally resides in combinations of formulation, device, and regulatory data because each reduces development risk for a commercial partner.

What revenue exposure and launch scenarios should investors assess?

IYUZEH revenue is exposed to three opposing forces:

1. Growth in preservative-free glaucoma prescribing.
2. Substitution by inexpensive generic latanoprost.
3. Entry by competing preservative-free products.

Launch scenario analysis

Scenario	Market effect
No near-term preservative-free generic	Supports premium pricing and physician adoption
Paragraph IV challenge with settlement	May produce an agreed future launch date and limited early competition
Successful early generic launch	Compresses price and pharmacy access
Multiple preservative-free entrants	Converts the segment into a formulation and device price competition
Strong payer preference for preservative-free products	Supports volume despite premium pricing
Weak reimbursement differentiation	Limits uptake to selected patients and specialists

The most defensible commercial niche is chronic glaucoma therapy for patients with ocular-surface disease, intolerance to BAK, multiple topical medications, or a clinical preference for preservative-free treatment.

What FDA regulatory issues affect follow-on IYUZEH products?

A follow-on product must address more than active-ingredient identity. FDA review will focus on:

• Pharmaceutical equivalence.
• Formulation composition.
• Sterility assurance.
• Container-closure integrity.
• Drop size and delivered dose.
• Stability and degradation products.
• Labeling and storage conditions.
• Microbial contamination risk during use.
• Device performance, if the container is integral to dosing.
• Patent certifications and any applicable regulatory exclusivity.

A conventional ANDA may be feasible if the product can demonstrate the required sameness and meet patent-certification requirements. A materially different formulation or delivery system may require a different regulatory pathway, depending on the extent of the changes and FDA’s determination.

Key Takeaways

• IYUZEH is a preservative-free latanoprost 0.005% ophthalmic solution approved under NDA 217951 in December 2023.
• Its excipient system uses glycerin, citrate buffering agents, sodium hydroxide, and water for injection.
• The main commercial differentiation is the removal of BAK, not a new active ingredient.
• The most valuable intellectual property is likely to involve formulation, stability, sterile manufacturing, and preservative-free delivery.
• Generic challengers can pursue alternative buffers, tonicity agents, packaging systems, and unit-dose presentations.
• The principal commercial risk is substitution by low-cost generic latanoprost and future preservative-free entrants.
• The strongest partnership opportunities involve multidose preservative-free devices, sterile ophthalmic manufacturing, regional commercialization, and platform formulation technology.

Frequently Asked Questions

Is IYUZEH a generic version of latanoprost?

IYUZEH contains the established active ingredient latanoprost, but it is marketed as a branded preservative-free ophthalmic product. Its differentiation is the formulation and delivery approach.

Does IYUZEH contain benzalkonium chloride?

No. IYUZEH is labeled as preservative-free and does not use benzalkonium chloride as a preservative.[1]

What is the main excipient opportunity in preservative-free glaucoma products?

The main opportunity is a stable, comfortable, sterile formulation that works with a multidose container without conventional antimicrobial preservatives.

Can a competitor use a different buffer to develop a follow-on product?

Potentially. A different buffer may provide a design-around route, but the applicant must establish stability, ocular tolerability, sterility, container compatibility, and FDA compliance.

Are biosimilars relevant to IYUZEH?

No. IYUZEH contains a small-molecule active ingredient, not a biologic. Competition would arise through generic or follow-on ophthalmic products rather than biosimilars.

References

1. U.S. Food and Drug Administration. (2023). IYUZEH (latanoprost ophthalmic solution) prescribing information. FDA.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: FDA-approved drugs database, IYUZEH NDA 217951. FDA.

4. U.S. Food and Drug Administration. (2024). Guidance for industry: Sterile drug products produced by aseptic processing, current good manufacturing practice. FDA.